StemSight raised €2.3M in a funding round led by Voima Ventures to advance stem cell therapy for corneal blindness.
PRIVATEFeb 14, 2025
Amount Raised
€2.3 Million
Round Type
Seed
TampereBiotechnologyHealth CareTherapeutics
Investors
Stephen Industries Inc.Biothom OyBusiness FinlandVoima Ventures
Description
Tampere-based biotech startup StemSight has raised €2.3 million to advance its stem cell-based therapy for limbal stem cell deficiency. The investment will fund preclinical studies, R&D, and manufacturing pilots to prepare for clinical trials.
Who to call at StemSight, and when
A new round usually means StemSight is about to hire and buy. The teams that reach out first get the meeting.
An alert the day StemSight raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at StemSight, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at StemSight. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
StemSight
Location
Tampere, Pirkanmaa, Finland
About
StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment StemSight raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
TampereBiotechnologyHealth CareTherapeutics